The field of geroscience has made significant strides in identifying mechanisms and pathways that can be targeted to delay or even reverse age-related decline.

Among these are genetic and dietary interventions, such as modulating the insulin/insulin-like growth factor-1 signaling pathway and caloric restriction, which have been shown to modulate lifespan across various species.

Pharmacological interventions have also been identified, including drugs like nor-dihydroguaiaretic acid, aspirin, acarbose, 17-α-estradiol, and the mTOR inhibitor rapamycin, which have shown to extend lifespan in genetically heterogeneous mice.

In light of these promising findings, EWHA DrugDesignHouse is eager to develop a new therapeutic agent that utilizes a unique chemical molecular structure to extend healthy lifespan.

The research and development team is diligently exploring potential drug candidates that can modulate aging-related pathways and promote longevity.

The company is also investigating the potential of drugs like senolytics and metformin, which have shown promise in preclinical studies for extending healthspan and delaying aging.

With these exciting developments, there is growing hope for the development of new drugs that can address age-related decline and help people live longer, healthier lives.